CWM
ALNY icon

Cranbrook Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cranbrook Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-39
Closed -$5K – 387
2020
Q4 		$5K Buy
+39
New +$5.21K ﹤0.01% 265

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cranbrook Wealth Management's ALNY Position: Q1 2021 in Review

Cranbrook Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2021, closing a stake of 39 shares — an estimated $5K sold.

Cranbrook Wealth Management first reported a position in ALNY in Q4 2020 and held it in 1 quarter. The position peaked at $5K in Q4 2020. 391 funds tracked by Wall St. Rank hold ALNY as of Q1 2021.

  • Cranbrook Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Cranbrook Wealth Management sold 39 Alnylam Pharmaceuticals shares in Q1 2021, an estimated $5K.
  • Cranbrook Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Cranbrook Wealth Management's Alnylam Pharmaceuticals position peaked at $5K in Q4 2020.
  • 391 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2021.

Based on Cranbrook Wealth Management's 13F filing for Q1 2021, filed 6 May 2021.